Deca Durabolin Medical Status and Research History

Deca Durabolin is a historic medicine name for nandrolone decanoate, an injectable anabolic androgenic steroid with a documented United States approval and research history. FDA records state that Deca Durabolin was initially approved on 5 October 1962 and was later recognized as effective for management of anemia associated with renal insufficiency. Organon stopped marketing the United States product in 2002.

Discontinued does not mean FDA found the product unsafe or ineffective. In 2010, FDA reviewed the withdrawal and determined that Deca Durabolin had not been removed from sale for reasons of safety or effectiveness. The product remained on the discontinued drug list, and FDA stated that generic applications referring to it could still be considered if the other regulatory requirements were satisfied.

Research history is broader than the former United States indication. Nandrolone decanoate was studied in renal anemia, hemodialysis, osteoporosis and other catabolic or wasting settings. Those studies describe particular patient groups and cannot be converted into a bodybuilding indication.

Sources checked 3 September 2026. Historical research and regulatory records are presented for context. They do not provide a dose, cycle, stack, injection schedule, product source or personal treatment recommendation.

What is Deca Durabolin?

Deca Durabolin is an established trade name for nandrolone decanoate. Nandrolone decanoate is an esterified form of nandrolone designed for prolonged release after intramuscular administration.

FDA substance records identify nandrolone decanoate with molecular formula C28H44O3 and UNII H45187T098. The active steroid entity is nandrolone after the ester is cleaved.[1]

Deca Durabolin medical identity
Trade name Deca Durabolin
Reference compound Nandrolone decanoate
Active steroid entity Nandrolone
Drug family Anabolic androgenic steroid
Molecular formula C28H44O3
UNII H45187T098
Historic United States dosage form Intramuscular injection
Historic United States medical role Management of anemia associated with renal insufficiency

A chemical identity record and a medicine approval record are not the same thing. The substance can continue to exist in databases, law and research after a particular branded presentation stops being marketed.

When was Deca Durabolin approved in the United States?

FDA stated in its 2010 regulatory review that Deca Durabolin was initially approved on 5 October 1962. The product was associated with Organon and later appeared in FDA records as nandrolone decanoate injection.

The approval predates many parts of the modern drug approval system. Older medicines were later reevaluated through federal programs created to assess evidence of effectiveness for drugs that had entered the market under earlier standards.

Selected Deca Durabolin regulatory timeline
Date Regulatory event Meaning
5 October 1962 Deca Durabolin was initially approved in the United States Establishes a genuine medicine approval history
1970s Controlled human studies investigated renal anemia and dialysis patients Provided evidence for erythropoietic effects
15 July 1983 FDA published its Drug Efficacy Study Implementation findings FDA recognized nandrolone decanoate as effective for specified renal anemia use
1980s to 1990s Research expanded into osteoporosis and bone mass Added evidence outside the United States renal anemia indication
21 May 2002 Organon notified FDA that it was no longer marketing the product The branded presentation moved to the discontinued drug list
7 May 2009 A citizen petition asked FDA whether withdrawal was linked to safety or effectiveness Triggered a formal FDA review
10 August 2010 FDA published its determination FDA found that Deca Durabolin had not been withdrawn for reasons of safety or effectiveness
2026 Nandrolone remains federally controlled and prohibited in tested sport Legal control and sport rules remain separate from the historic medicine record

What was the Drug Efficacy Study Implementation review?

The Drug Efficacy Study Implementation program reevaluated medicines that had entered the United States market before modern effectiveness requirements were fully established.

FDA’s 2010 notice states that under this program the agency concluded that nandrolone decanoate was effective for the indications described in a Federal Register notice published on 15 July 1983.

This is an important part of the Deca Durabolin history because the medicine was not simply carried forward on the basis of its 1962 status. Its effectiveness record underwent later federal review.

What the federal efficacy review establishes
Question Record
Did Deca Durabolin have a United States medicine approval? Yes. FDA records an initial approval date of 5 October 1962.
Was effectiveness later examined? Yes. Nandrolone decanoate was considered through the Drug Efficacy Study Implementation process.
What use was retained in the FDA record? Management of anemia associated with renal insufficiency.
Did this create a physique or performance indication? No.
Did the review mean the product would remain marketed forever? No. Marketing status later changed.

What was Deca Durabolin used for medically in the United States?

The historic United States Deca Durabolin record identifies management of anemia associated with renal insufficiency. FDA states that the drug had been shown to increase hemoglobin and red cell mass.[2]

Renal anemia occurs when chronic kidney disease reduces the body’s capacity to maintain normal red blood cell production. Before recombinant erythropoietin became widely available, androgens were one of the therapeutic approaches investigated for this problem.

Historic medical purpose versus unsupported transfer
Medical record What it establishes What it does not establish
Renal anemia Nandrolone decanoate was used to improve red blood cell production in selected patients A general performance indication
Higher hemoglobin The compound can stimulate erythropoiesis That increasing hematocrit is desirable in a healthy person
Hemodialysis research The compound was studied in severe kidney disease under medical supervision Evidence for healthy recreational exposure
Regulated medicine The studied product had defined pharmaceutical identity That an unregulated vial contains nandrolone decanoate

Read anabolic steroids in medicine for the wider history of therapeutic androgen use.

When did Deca Durabolin stop being marketed in the United States?

Organon notified FDA in a letter dated 21 May 2002 that it was no longer marketing Deca Durabolin injection in the United States. FDA then moved the product to the discontinued drug product list in the Orange Book.

Discontinued marketing does not automatically mean FDA withdrew approval because of a safety problem, lack of effectiveness or regulatory failure. Companies stop marketing medicines for many reasons, including changes in medical practice, economics, manufacturing strategy and demand.

Why the word discontinued needs context
Statement Accurate? Reason
Deca Durabolin disappeared because FDA found it unsafe No FDA specifically found that the product was not withdrawn for reasons of safety or effectiveness
The brand stopped being marketed in the United States Yes Organon notified FDA in 2002
Discontinued means the medicine never had approval No FDA records initial approval in 1962
The old branded product remains a routine current United States medicine No The branded product remains on the discontinued list
FDA’s 2010 finding left a regulatory route for generic applications Yes FDA stated that qualifying abbreviated applications could still be approved

What did FDA determine about Deca Durabolin in 2010?

A 2009 citizen petition asked FDA to determine whether Deca Durabolin had been withdrawn from sale because of safety or effectiveness concerns.

FDA reviewed its records, relevant literature and postmarketing information. The agency stated that it found no information indicating that Deca Durabolin had been withdrawn for safety or effectiveness reasons.[2]

FDA kept the product in the discontinued portion of the Orange Book and stated that abbreviated applications referring to Deca Durabolin could be approved if the other legal and regulatory requirements were met.

FDA’s 2010 finding in plain language
Question FDA finding
Was the product still marketed by Organon? No
Was withdrawal linked to a proven safety reason? FDA said no
Was withdrawal linked to lack of effectiveness? FDA said no
Could the product remain a reference for a generic application? Yes, subject to the normal legal and regulatory requirements
Did FDA erase the known adverse effect record? No

What did early nandrolone research find in renal anemia?

Renal anemia was one of the best studied medical uses of nandrolone decanoate. Several trials in the 1970s examined people with chronic kidney failure receiving hemodialysis.

A controlled study published in 1974 examined nandrolone decanoate in patients receiving maintenance hemodialysis. Mean red cell mass and hematocrit increased during androgen treatment, and transfusion requirements fell.[3]

Another controlled study published in 1974 investigated nandrolone decanoate in hemodialysis patients and contributed to the evidence base for androgen treatment of renal anemia.[4]

Selected renal anemia research
Research Population Main question Evidence lesson
Hendler and colleagues, 1974 Maintenance hemodialysis patients Could nandrolone improve anemia? Red cell mass and hematocrit improved during treatment
Williams and colleagues, 1974 Hemodialysis patients Response to nandrolone decanoate Added controlled clinical evidence
Doane and colleagues, 1975 Women receiving chronic hemodialysis Does kidney status affect response? Many patients showed increased hematocrit, with variable response
Buchwald and colleagues, 1977 Chronic hemodialysis patients Effect on anemia Further randomized evidence examined erythropoietic response
Naik and colleagues, 1978 End stage renal disease with dialysis Double blind crossover response No sustained significant rise was found among study completers

The mixed results are important. Nandrolone had genuine erythropoietic effects, but not every trial found the same magnitude of benefit and not every patient responded.

Why was nandrolone decanoate used in people receiving hemodialysis?

Diseased kidneys may produce less erythropoietin, the hormone that helps regulate red blood cell production. Before recombinant erythropoietin became established, clinicians had fewer ways to address chronic renal anemia.

Androgens can stimulate erythropoiesis through several mechanisms. Older studies measured hemoglobin, hematocrit, red cell mass, transfusion requirements and erythropoietic response.

Why dialysis research should not be generalized to healthy people
Characteristic Dialysis research Healthy nonmedical exposure
Baseline red blood cell status Anemia was present Often normal before exposure
Treatment aim Correct deficient red blood cell production No renal anemia treatment goal
Medical supervision Hemoglobin, hematocrit and kidney disease were monitored Monitoring may be absent or inconsistent
Product identity Defined pharmaceutical nandrolone decanoate Product identity may be uncertain
Risk from higher hematocrit Correction toward a therapeutic target was the aim Increasing an already normal value can create a different risk profile

How did recombinant erythropoietin change the medical role of nandrolone?

Recombinant human erythropoietin changed treatment of renal anemia by directly replacing the deficient erythropoietic signal. This reduced reliance on anabolic steroids for many dialysis patients.

Later research compared nandrolone with erythropoietin or investigated nandrolone as an adjunct. A controlled trial published in the early 1990s found that adding nandrolone to the erythropoietin regimen used in that study did not significantly improve the hematocrit response and produced adverse effects including acne.[8]

Other later work continued to report useful hematologic responses in selected dialysis populations, which shows that the change in medical practice was not based on the claim that nandrolone had no biological effect.

Why nandrolone’s place in renal anemia changed
Era Therapeutic context Effect on nandrolone’s role
Before recombinant erythropoietin Few targeted ways to stimulate red cell production Androgens had a larger therapeutic role
After erythropoietin became available A more direct erythropoietic treatment existed The relative role of anabolic steroids declined
Later adjunct research Researchers tested whether nandrolone could add benefit or reduce treatment burden Results varied by study and population
Modern practice Renal anemia care uses newer evidence and therapies Historic nandrolone studies should not be treated as a current default treatment pathway

Why was nandrolone decanoate studied for osteoporosis?

Nandrolone decanoate was also investigated because anabolic and androgenic signalling can influence muscle mass, bone turnover and mineral balance.

Several controlled studies in postmenopausal women examined bone mineral content, bone mineral density, bone pain, calcium metabolism and fracture outcomes.

A 1986 double blind controlled study in patients with symptomatic osteoporosis reported increased bone mineral content in the nandrolone group and a lower fracture rate during the second year compared with the other treatment groups.[9]

A 1989 controlled trial in postmenopausal women with osteoporotic fractures found a significant increase in one forearm bone mineral measure compared with placebo, while other bone sites showed trends that did not reach statistical significance.[10]

Did nandrolone decanoate increase bone density?

Several studies reported increases in bone mineral measures, but the findings were not identical across skeletal sites, study designs or time periods.

A randomized placebo controlled study published in 1993 followed postmenopausal women with established osteoporosis. Vertebral bone mineral density increased in the nandrolone group while decreasing in the placebo group. Bone pain also improved. Two treated patients withdrew because of hirsutism and hoarseness.[12]

Selected osteoporosis findings
Study Population Finding Important limit
Geusens, 1986 Symptomatic osteoporosis Bone mineral content increased in measured areas Small historical treatment study
Need and colleagues, 1987 Postmenopausal osteoporosis Forearm mineral and calcium metabolism were assessed Short treatment interval
Gennari and colleagues, 1989 Postmenopausal osteoporosis Lumbar bone mineral measures increased in the treated group Small sample
Johansen and colleagues, 1989 Postmenopausal women with osteoporotic fracture A significant increase occurred in one forearm measurement Not every skeletal site showed a significant difference
Passeri and colleagues, 1993 Established postmenopausal osteoporosis Vertebral bone mineral density improved versus placebo Virilizing adverse effects caused withdrawal in some patients

These studies document a real research history. They do not establish nandrolone decanoate as a preferred modern osteoporosis treatment.

What did osteoporosis trials reveal about nandrolone in women?

Research in postmenopausal women showed both bone related effects and androgen related adverse effects.

The 1993 placebo controlled osteoporosis trial reported withdrawal of two nandrolone treated participants because of hirsutism and hoarseness. These outcomes fit the broader virilization warnings attached to androgen therapy.

This creates an important evidence pattern: a treatment can improve a measured disease outcome while still producing unwanted androgenic effects.

Benefit and adverse effect can coexist in the same research record
Observed area Research finding
Bone mineral density Improvement was reported in selected measures
Bone pain Some studies reported symptomatic improvement
Hemoglobin Can rise during androgen treatment
Hirsutism Occurred in treated women in clinical research
Voice change Hoarseness or voice change was reported and can be persistent
Blood lipids Some trials reported unfavorable changes

See anabolic steroid effects in women for the wider female health record.

Why did nandrolone studies sometimes reach different conclusions?

Medical studies do not need to produce identical results to remain useful. Nandrolone research differed in patient age, sex, kidney function, dialysis status, severity of anemia, iron status, outcome measures and duration of follow up.

One 1978 double blind crossover dialysis trial did not find a sustained significant increase in hemoglobin or red cell mass among the patients who completed the trial. Earlier controlled work had found meaningful increases in these outcomes.[7]

The appropriate reading is not that one paper proves nandrolone works and another proves it does not. The studies show variable response across small and clinically different populations.

Reasons older nandrolone studies can differ
Difference Why it changes interpretation
Kidney status People with functioning kidneys and people without kidneys can respond differently
Baseline anemia A more severe erythropoietic deficit can alter response
Iron status Red blood cell production depends on adequate substrate
Study duration Hematologic and skeletal outcomes develop over different time frames
Comparator Placebo, calcium treatment and erythropoietin answer different clinical questions
Outcome measure Hemoglobin, red cell mass, bone density and fracture rate are not interchangeable
Small samples Many historic trials lacked the statistical power expected from modern large studies

Why is Deca Durabolin less prominent in modern medicine?

The therapeutic environment changed. Recombinant erythropoietin and later anemia treatments provided more targeted options for chronic kidney disease. Osteoporosis care also developed medicines supported by larger modern evidence programs.

This does not erase nandrolone’s research history. It changes the practical place of that evidence in current medicine.

Historic role compared with modern treatment context
Health problem Historic nandrolone role Why the context changed
Renal anemia Androgen stimulation of erythropoiesis Erythropoiesis stimulating medicines changed treatment
Osteoporosis Bone density and pain were investigated Modern osteoporosis therapies have larger dedicated evidence programs
Catabolic illness Anabolic effects were medically attractive Later therapies can target the underlying disease or nutritional pathway more directly

A historic medicine can remain scientifically informative after its former place in routine care has narrowed.

Is nandrolone a controlled substance in the United States?

Yes. Nandrolone is listed as a Schedule III controlled anabolic steroid under federal law. The Drug Enforcement Administration associates nandrolone with controlled substance code 4000 and includes Deca Durabolin among its recognized names.

Controlled substance status is separate from FDA medicine status. FDA regulates drug applications, labelling and marketing. DEA scheduling regulates possession, prescribing, distribution and other controlled substance activities under federal law.

United States regulatory layers
Regulatory layer Question answered Nandrolone record
Historic FDA approval Did Deca Durabolin have an approved medicine record? Yes
Current branded marketing Is the old Organon United States product still marketed? No
Reason for discontinuation Did FDA find it was withdrawn for safety or effectiveness reasons? No
Controlled substance law Is nandrolone federally controlled? Yes, Schedule III
Sport regulation Can it be used freely in tested competition? No

How is nandrolone controlled in the United Kingdom?

The United Kingdom Home Office common controlled drug list records nandrolone as a Class C drug in Schedule 4 Part 2.[14]

Schedule 4 Part 2 contains anabolic substances. The legal treatment of possession, import, export, supply and medicinal products is not identical, so the classification should not be reduced to a single statement that nandrolone is simply legal or illegal.

United Kingdom nandrolone status
Drug Nandrolone
Misuse of Drugs Act class Class C
Misuse of Drugs Regulations schedule Schedule 4 Part 2
Interpretation Specific conduct must be checked against current legislation

How is nandrolone classified in Canada?

Canada includes nandrolone within the anabolic steroid framework of Schedule IV of the Controlled Drugs and Substances Act.

Canadian controlled drug status should be read independently from United States scheduling or United Kingdom classification. Each jurisdiction defines possession, trafficking, importation, prescribing and other activities through its own statutes and regulations.

Is nandrolone prohibited in competitive sport?

Yes. Nandrolone is an anabolic agent under the World Anti Doping Agency prohibited framework. Anabolic agents are prohibited at all times in athletes governed by the Code.

A genuine medical history does not give an athlete automatic permission to use a prohibited substance. Medical need and sport authorization are separate processes.

Medicine history and sport status are separate
Fact Meaning
Nandrolone has a medical history It has been used and researched therapeutically
Nandrolone is an anabolic agent It falls within the prohibited anabolic agent category in tested sport
A physician once prescribed nandrolone This does not automatically satisfy current anti doping requirements
A product is sold as Deca Durabolin The name does not establish sport eligibility or product identity

This page does not provide detection times, clearance estimates, masking methods or testing workarounds.

Does Deca Durabolin’s medicine history authenticate products sold today?

No. The historic Organon product and its regulatory record describe a defined pharmaceutical medicine. A vial carrying the same trade name outside a regulated supply chain does not inherit that identity automatically.

There are two separate questions: what nandrolone decanoate is, and what is inside a particular vial. Chemical databases answer the first. Only reliable product provenance or appropriate analytical testing can help with the second.

What common records can establish
Record Can establish Cannot establish
FDA substance record Reference identity of nandrolone decanoate Contents of a current vial
Historic medicine approval Regulated Deca Durabolin history Approval of an unrelated product using the same name
Clinical study Findings in the population studied Authenticity of a seller’s product
Packaging What the label claims Independent confirmation of the active ingredient
Laboratory analysis Findings for the submitted sample and method Contents of every later batch

What can Deca Durabolin research establish, and where does it stop?

The research establishes that nandrolone decanoate can have clinically measurable effects on erythropoiesis, blood measures, bone mineral outcomes, body composition and androgen sensitive tissues.

The same research also records adverse effects and variation between patients. Medical benefit in anemia or osteoporosis does not establish an acceptable risk profile for healthy nonmedical use.

Supported medical inference versus unsupported transfer
Evidence Supported interpretation Unsupported interpretation
Renal anemia trials Nandrolone can stimulate red blood cell production in some patients Higher hematocrit is always beneficial
Osteoporosis trials Nandrolone affected selected bone mineral outcomes It is a preferred modern osteoporosis medicine
Research in women Therapeutic effects and virilizing effects can occur together Medical research proves women cannot experience androgenic adverse effects
1962 approval Deca Durabolin had a genuine United States medicine history Every current product using the name has FDA medicine status
2010 FDA finding Discontinuation was not attributed to safety or effectiveness reasons Nandrolone has no meaningful health risks
Schedule III status Nandrolone remains federally controlled Controlled substance status describes medical effectiveness

The most reliable reading keeps the population, medical aim, product identity, date and regulatory question attached to each claim.

References

  1. Nandrolone decanoate substance record. United States Food and Drug Administration. Chemical identity, formula and substance identifiers.
  2. Determination that Deca Durabolin was not withdrawn from sale for reasons of safety or effectiveness. United States Food and Drug Administration. Federal Register. 10 August 2010. Records the initial 1962 approval, the 1983 efficacy review, the former renal anemia indication, the 2002 marketing discontinuation and FDA’s 2010 finding.
  3. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. New England Journal of Medicine. 1974. PMID 4606387.
  4. Nandrolone decanoate therapy for patients receiving hemodialysis: a controlled study. Archives of Internal Medicine. 1974. PMID 4602048.
  5. Response of uremic patients to nandrolone decanoate. Archives of Internal Medicine. 1975. PMID 1156056.
  6. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron. 1977. PMID 323739.
  7. Androgen trial in renal anaemia. Proceedings of the European Dialysis and Transplant Association. 1978. PMID 368770.
  8. Controlled trial of recombinant human erythropoietin and nandrolone decanoate in chronic hemodialysis. Clinical research comparing erythropoietin alone with combined treatment. PMID 1606777.
  9. Long term effect of nandrolone decanoate on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis. Bone and Mineral. 1986. PMID 3333018.
  10. Treatment of postmenopausal osteoporosis: is nandrolone decanoate a candidate?. Bone and Mineral. 1989. PMID 2665884.
  11. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established postmenopausal osteoporosis. Maturitas. 1989. PMID 2687645.
  12. Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas. 1993. PMID 8133796.
  13. Double blind placebo controlled trial of treatment of osteoporosis with nandrolone decanoate. Osteoporosis International. 1993. PMID 8461566.
  14. List of commonly encountered controlled drugs. United Kingdom Home Office. Nandrolone is listed as Class C, Schedule 4 Part 2.
  15. Controlled substances Orange Book. United States Drug Enforcement Administration. Nandrolone is included in Schedule III under controlled substance code 4000.
  16. Controlled Drugs and Substances Act, Schedule IV. Government of Canada. Anabolic steroid scheduling record.
  17. The 2026 Prohibited List. World Anti Doping Agency. Anabolic agents are prohibited at all times.
  18. Diagnosis and management of anabolic androgenic steroid use. Journal of Clinical Endocrinology and Metabolism. Clinical context for nonmedical anabolic steroid exposure and health assessment.